Clinical application of GnRHa before uterine myomectomy: report of 20 cases

Abstract

Abstract: Objective To study the clinical application of GnRHa prior to uterine myomectomy and its effect on the clinical outcome of pregnancy. Methods A retrospective review of the medical records in 20 cases of uterine myomectomy over a period of 6 years was performed. The changes of uterus and myoma volumes in response to preoperative GnRHa was observed, and the rate of relapse in the follow-up, time of impregnation, spontaneous abortion after the impregnation, time of delivery after the operation and the aura threatening uterine rupture, and uterine rupture during the delivery were assessed. Results Application of GnRHa produced significant improvement in the clinical symptoms and resulted in obviously reduced volumes of the uterus and myoma. The myoma volume reduction was close to 50% in these cases, and relapse occurred in only 1 case. No spontaneous abortion was found after GnRHa application. The average time of pregnancy was 34±3.5 weeks, and aura for uterine rupture was found in 1 case at 33 weeks of pregnancy after GnRHa application. Conclusion Application of GnRHa can correct anemia, decrease the relapse rate of myoma, reduce uterus and myoma volumes, to make possible smaller incision for uterine myomectomy that leaves smaller scar in the uterus and decrease intraoperative bleeding, also relieving endometrial injuries to promote the conditions for impregnation and minimize the risks of uterine rupture and total hysterectomy for the benefit of normal delivery.

CLC Number:

YU Yan-hong, GONG Shi-peng, WAN Shu-mei. Clinical application of GnRHa before uterine myomectomy: report of 20 cases[J]. Journal of Southern Medical University, 2004, 24(03): 317-319.

References

[1] 林巧雅.妇科肿瘤学[M].北京:人民卫生出版社,2000.317.
[2] 李少波,周顺科.子宫肌瘤的治疗方法与展望[J].肿瘤研究与临床(Cancer Res Clin),2002,14(4):284-7.
[3] 魏永志.子宫肌瘤药物研究进展[J].河北医药(J Hebei Med), 2001,23(7):543-5.
[4] Guamaccia MM, Rein MS. Traditional surgical approaches to uterine fibroids abdominal myomectomy and hyserectomy [J]. C lin Obstet Gynecol, 2001, 44(2): 385-400.
[5] 左常婷.子宫肌瘤手术治疗进展[J].实用妇产科杂志(Pract J Obstet Gyneco1),2000,1 6(4):1 83-5.
[6] Filicori M.A conservative approach to the management ofuterine leiomyoma:pituitary desensitization by aluteinzing hormone releasing analogue[J].Am J Obstect Gynecol,1983,147:726-8.
[7] BrunereauL,Herbreteau D,Gallas S,et al.Uterine arteryembolization in the primarytreatment ofuterineleiomyomas;technical fea-tures and prospective follow-up with clinical and asonographic examinationsin 58 patients[J].AJR Am J Roentgenol,2000,175(5):1267-72.
[8] Jha RC,Ascher SM,Imaoda I, et al.Symptomatic fibroleimyomoto: MR imagingoftheuterus beforus before and after uterine arterial embolization[J].Radiology,2000,217(1):228-35.
[9] Deligdisch L, Hirschmanu S,Altchek A.Pathologic changes in gonadotropin releasing bormone agonist analogue treated uterineleiomyomata[J].Fertil Steril,1997,67(5):837-41.
[10] 李丽华,王秀云,吴燕.手术前应用促性腺激素释放激素激动剂用于子宫肌瘤合并贫血的治疗[J].中华妇产科杂志,1998,33(9):563-4.Li LH, Wang XY, Wu Y. GnRHa treat myoma of uterus patients fol lowed anemia before preoperative[J]. Chin J Obstet Gynecol, 1998,33(9): 563-4.
[11] 朱云晓,柯宫琪.子宫肌瘤非手术治疗研究新进展[J].国外医学@妇幼保健分册(Foreign Med@Women Children Health Sect),2002,13(3):116-9.
[12] Nakayama H, Yano T, Sagara Y, et al. Estviol addback therapy in the long-acting gonadotropin releasing hormone agonist treatmentof uterine leiomyomata[J]. Gynecol Endocrinol, 1999, 13(6): 382-9.
[13] 徐苓.子宫肌瘤非手术治疗的理论基础和适应症[J].中华实用妇科和产科杂志,2001,17(3):129-30.Xu L. Themry background and adaptation of no-operating treatmentto uterine leiomyoma[J]. Chin J Uti Obstet Gynecol, 2001, 17(3):129-30.

[1]	. [J]. Journal of Southern Medical University, 2006, 26(12): 1772-1773.
[2]	ZHANG Yu1, ZHANG Yi1, LIN Qiu-hua2 1Department of Obstetrics and Gynecology, Xiangya Hospital, 2Department of Obstetrics and Gynecology, Second Xiangya Hospital, Central South University, Changsha 410078, China. Progesterone-modulated proteins in human endometrial cancer cell line Ishikawa [J]. Journal of Southern Medical University, 2006, 26(08): 1110-1113.
[3]	LU Jin-li1, YANG Fang2 Department of Radiotherapy, First Hospital1, Western District Library2, Xi’an Jiaotong University, Xi’ an 710061, China. Clinical pharmacokinetic study of cisplatin in enhancing cervical cancer radiosensitivity [J]. Journal of Southern Medical University, 2006, 26(08): 1170-1172.
[4]	. [J]. Journal of Southern Medical University, 2006, 26(08): 1248-1249.
[5]	GUO Sui-qun1, XING Fu-qi1, PANG Zhan-jun1, FANG Wei-yi2, LIU Guo-bing1 1Department of Gynaecology and Obstetrics, Nanfang Hospital, 2Institute of Cancer Research, Southern Medical University, Guangzhou 510515, China. Preliminary study of gene expression profiling in human type I and II endometrial carcinoma [J]. Journal of Southern Medical University, 2006, 26(06): 734-737.
[6]	WANG Ying, LI Xu, CHEN Wei Medical Laboratory Center, First Hospital of Xi’an Jiaotong University, Xi’an 710061, China. Expression, structure prediction and functional analysis of murine single-chain fragment vari- able antibody against human cervical cancer [J]. Journal of Southern Medical University, 2006, 26(01): 16-21.
[7]	LIU Guo-bing, LIU Xin, PANG Zhan-jun, XING Fu-qi. Significance of pelvic lymph node human papillomavirus DNA detection in cervical cancer [J]. Journal of Southern Medical University, 2005, 25(10): 1236-1239.
[8]	LIU Xin, LIU Guo-bing, PANG Zhan-jun, XING Fu-qi. Sequence polymorphism of human papillomavirus type 16 E7 in cervical cancer [J]. Journal of Southern Medical University, 2005, 25(10): 1272-1275.
[9]	LANG Yan¹, XIONG Yong-yan¹, CHEN Hui-zhen². Association between expression of survivin and high-risk human papillomavirus infection in cervical cancer and precancerous tissues [J]. Journal of Southern Medical University, 2005, 25(10): 1276-1279.
[10]	ZHAO En-feng¹, BAO Lei², LI Chao, SONG Lei³, LI Ya-li¹. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years [J]. Journal of Southern Medical University, 2005, 25(06): 605-609.
[11]	ZHENG Xiao-kang¹, CHEN Long-hua¹, LI Jian². Radiotherapeutic effect and prognosis of bulky exophytic cervical cancer [J]. Journal of Southern Medical University, 2005, 25(03): 332-334,338.
[12]	ZHOU Jin¹, CHEN Shi-ling¹, XING Fu-qi¹, PANG Zhan-jun¹, LI Bing², ZHOU Wen-qu², FU Xin², DING Yan-qing³. Association of the novel hydatidiform mole-related gene F10 with the invasiveness of trophoblastic tumor [J]. Journal of Southern Medical University, 2005, 25(02): 171-173.
[13]	. Diagnostic analysis of two sister pairs with endometrial cancer [J]. Journal of Southern Medical University, 2005, 25(02): 239-240.
[14]	LIU Ke¹, WANG Li-li², SUN Fang¹, ZHENG Yan-fang³, ZHANG Ji-ren³. Effect of anti-HPV16 E6-ribozyme on cell proliferation and invasiveness of cervical carcinoma cell line CaSKi [J]. Journal of Southern Medical University, 2004, 24(12): 1367-1372.
[15]	ZHOU Rui-li, LIU Guo-bing. Age and prognosis: analysis of their association in 93 cases of cervical cancer [J]. Journal of Southern Medical University, 2004, 24(09): 1066-1067.